Regeneron Pharmaceuticals Inc (REGN): Is This Eye Drug Worth The Hype?

Page 1 of 2

Editor’s Note: The original article incorrectly references Lucentis’ and Eylea’s dosage instructions. This has been corrected and Motley Fool sincerely apologizes for the error.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) should spike– every time there’s a slight pullback the stock shoots higher. Last Thursday Regeneron gained almost 10% behind a positive Phase 3 trial for its drug Eylea.

Regeneron Pharmaceuticals is a $25 billion biopharmaceutical company with three approved products and annual sales of $1.59 billion. Right away, that ratio not might look right, as a $25 billion company should have more revenue than $1.59 billion. But, its stock price is counting on growth, as it has 13 products being tested in clinical trials, and three different drugs in Phase 3 (five total studies).

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Taking a look at Eylea

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is one of the most promising drug companies in the market, and it is because of Eylea. Currently, Eylea is used to treat “wet” age-related macular degeneration, the leading cause of blindness in the elderly. It is approved in the U.S., and Regeneron markets the drug exclusively – but Bayer markets the drug oversees and receives a royalty on oversees revenue.

While Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Bayer are partners in developing and marketing Eylea, there’s no question Eylea has been developed using the technology of Regeneron and is primarily Regeneron’s drug. Its most direct competition comes from RocheHoldings‘  drug Lucentis. Roche is the world’s largest vaccine developer, and when Eylea was launched many feared that it would not be able to compete with the presence of Roche and its drug.

Eylea set to expand

Eylea is quickly replacing all competition (including Roche’s Lucentis) as both Regeneron Pharmaceuticals Inc (NASDAQ:REGN)and Bayer have done a great job marketing the drug. Not to mention, Eylea is superior in that it only has to be injected once every two months; compared to monthly like other drugs.

However, there is another drug in the works that must be mentioned, and that is Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE)’ drug Optina. This drug treats the same condition, but instead of a needle to the eye, it is taken in pill form to repair blood vessels. But, Optina is still in clinical trials, awaiting data, and there are serious doubts the drug will be effective.

If Regeneron Pharmaceuticals Inc (NASDAQ:REGN) believed Optina would challenge its future sales, there’s no doubt it would buy the company. Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) trades at a market cap of just $220 million while Regeneron is a $25 billion powerhouse. And Regeneron has an incredible pipeline along with a drug that is growing and expanding. In short, it has the cash.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN), not counting proceeds to Bayer, is expected to achieve revenue of $1.3 billion this year. The drug is well on its way to blockbuster status and has accomplished this feat with the one application. Therefore, its 10% rise last Thursday shouldn’t serve as a surprise; as the data shows that Eylea works on other applications as well.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) produced positive top-line data for the treatment of myopic choroidal neovascularization (mCNV) in a Phase 3 trial. mCNV is a disease where abnormal blood vessels grow into the retina in people who are severely short-sighted. This disease is quite different from age-related macular degeneration, showing the potential diversification of the product.

The addition of mCNV won’t create billions in additional sales, but analysts predict that it could boost sales another $200 million in the U.S. alone. Last year, Roche’s Lucentis saw sales of $1.5 billion and it treats wet age related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. Basically, it treats a variety of diseases of the eye, and its revenue is expected to drop by about half in the next year. This cut is because of Regeneron Pharmaceuticals Inc (NASDAQ:REGN), and the fact that Eylea is well on its way to offering a wide range of treatments that are superior to existing treatments.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!